MCL1 inhibitors are designed to mimic BH3 domains and occupy the BH3-domain binding groove in MCL1, in this way blocking MCL1 interaction with the BH3 domains of other proteins and inducing cancer cell death [1,2]. The gene discussed is MCL1; the disease is cancer.